[{"notes_id":"1_499","category":"1","subcategory":"1","title":"Atrial fibrillation: anticoagulation","body":"NICE updated their guidelines on the management of atrial fibrillation (AF) in 2021. <br \/><br \/><h5 class='notes-heading'>Does the patient need anticoagulation?<\/h5><br \/>The need for anticoagulation should be considered in patients with any history of AF, not just if they are in AF currently, i.e. the following groups should be assessed:<br \/><ul><li>symptomatic or asymptomatic <span class=\"concept\" data-cid=\"5358\">paroxysmal<\/span>, persistent or permanent atrial fibrillation<\/li><li>atrial flutter<\/li><li>a continuing risk of arrhythmia recurrence after cardioversion back to sinus rhythm or catheter ablation<\/li><\/ul><br \/>NICE suggest using the <span class=\"concept\" data-cid=\"4020\"><b>CHA<sub>2<\/sub>DS<sub>2<\/sub>-VASc<\/b><\/span> score to determine the most appropriate anticoagulation strategy. This scoring system superceded the CHADS<sub>2<\/sub> score.<br \/><br \/><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid1\" ><thead><tr><th><\/th><th>Risk factor<\/th><th>Points<\/th><\/tr><\/thead><tbody><tr><td> <b>C<\/b><\/td><td>Congestive heart failure<\/td><td>1<\/td><\/tr><tr><td> <b>H<\/b><\/td><td>Hypertension (or treated hypertension)<\/td><td>1<\/td><\/tr><tr><td> <b>A<sub>2<\/sub><\/b><\/td><td>Age >= 75 years<\/td><td>2<\/td><\/tr><tr><td><\/td><td>Age 65-74 years<\/td><td>1<\/td><\/tr><tr><td> <b>D<\/b><\/td><td>Diabetes<\/td><td>1<\/td><\/tr><tr><td> <b>S<sub>2<\/sub><\/b><\/td><td>Prior Stroke, TIA or thromboembolism<\/td><td>2<\/td><\/tr><tr><td> <b>V<\/b><\/td><td>Vascular disease (including ischaemic heart disease and peripheral arterial disease)<\/td><td>1<\/td><\/tr><tr><td><b>S<\/b><\/td><td>Sex (female)<\/td><td>1<\/td><\/tr><\/tbody><\/table><\/div><br \/>The table below shows a suggested <span class=\"concept\" data-cid=\"1686\">anticoagulation strategy based on the score<\/span>:<br \/><br \/><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid2\" ><thead><tr><th>Score<\/th><th>Anticoagulation<\/th><\/tr><\/thead><tbody><tr><td>0<\/td><td>No treatment<\/td><\/tr><tr><td>1<\/td><td>Males: Consider anticoagulation<br \/>Females: No treatment (this is because their score of 1 is only reached due to their gender)<\/td><\/tr><tr><td>2 or more<\/td><td>Offer anticoagulation<\/td><\/tr><\/tbody><\/table><\/div><br \/>Remember that if a CHA<sub>2<\/sub>DS<sub>2<\/sub>-VASc score suggests no need for anticoagulation it is important to ensure a <span class=\"concept\" data-cid=\"10904\">transthoracic echocardiogram has been done to exclude valvular heart disease<\/span>, which in combination with AF is an absolute indication for anticoagulation.<br \/><br \/><br \/><h5 class='notes-heading'>Assessing bleeding risk<\/h5><br \/>Doctors have always thought carefully about the risk\/benefit profile of starting someone on warfarin. A history of falls, old age, alcohol excess and a history of previous bleeding are common things that make us consider whether anticoagulation is in the best interests of the patient., but NICE warn us <span class=\"concept\" data-cid=\"5359\">not to withhold anticoagulation solely on the grounds of age or risk falls<\/span>. NICE now recommend we formalise this risk assessment using the <span class=\"concept\" data-cid=\"11422\">ORBIT scoring system<\/span>. Previously the HAS-BLED scoring system was recommended.<br \/><br \/><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid3\" ><thead><tr><th>Variable<\/th><th>Points<\/th><\/tr><\/thead><tbody><tr><td><span class=\"concept\" data-cid=\"11423\">Haemoglobin<\/span> <130 g\/L  for males and < 120 g\/L for females, or haemtocrit < 40% for males and < 36% for females<\/td><td>2<\/td><\/tr><tr><td>Age > 74 years<\/td><td>1<\/td><\/tr><tr><td>Bleeding history (GI bleeding, intracranial bleeding or haemorrhagic stroke)<\/td><td>2<\/td><\/tr><tr><td><span class=\"concept\" data-cid=\"11423\">Renal impairment<\/span> (GFR < 60 mL\/min\/1.73m<sup>2<\/sup>)<\/td><td>1<\/td><\/tr><tr><td>Treatment with antiplatelet agents<\/td><td>1<\/td><\/tr><\/tbody><\/table><\/div><br \/>There are no formal rules on how we act on the ORBIT score and individual patient factors should be taken into account. However, the following table acts as a guide: <br \/><br \/><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid4\" ><thead><tr><th>ORBIT score<\/th><th>Risk group<\/th><th>Bleeds per 100 patient-years<\/th><\/tr><\/thead><tbody><tr><td>0-2<\/td><td>Low<\/td><td>2.4<\/td><\/tr><tr><td>3<\/td><td>Medium<\/td><td>4.7<\/td><\/tr><tr><td>4-7<\/td><td>High<\/td><td>8.1<\/td><\/tr><\/tbody><\/table><\/div><br \/><br \/><h5 class='notes-heading'>If treatment is indicated, which anticoagulant?<\/h5><br \/>For many years warfarin was the anticoagulant of choice in atrial fibrillation. This changed following the development of <span class=\"concept\" data-cid=\"3635\"><b>direct oral anticoagulants (DOACs)<\/b><\/span>. These have the advantage of not requiring regular blood tests to check the INR and now recommended as the first-line anticoagulant for patients with AF. If a patient was previously started on warfarin, NICE recommend discussing switching to a DOAC during a routine follow-up appointment.<br \/><br \/>The following DOACs are recommended by NICE for reducing stroke risk in AF:<br \/><ul><li>apixaban<\/li><li>dabigatran<\/li><li>edoxaban<\/li><li>rivaroxaban<\/li><\/ul><br \/>Warfarin is now used second-line, in patients where a DOAC is contraindicated or not tolerated.<br \/><br \/>Aspirin is not recommended for reducing stroke risk in patients with AF.","notes_hash":"3258e2d37601a26bf43d134847023b84","knowledge_graph_node_id_link":1162,"links":"<table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_885\" data-linkid=\"885\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_885\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">21<\/span><button type=\"button\" style=\"\" id=\"link_dislike_885\" data-linkid=\"885\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_885\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">22<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/guidance\/ng128\/chapter\/Recommendations\">2019 Stroke and transient ischaemic attack in over 16s: diagnosis and initial management<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>European Society of Cardiology<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1196\" data-linkid=\"1196\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_1196\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">18<\/span><button type=\"button\" style=\"\" id=\"link_dislike_1196\" data-linkid=\"1196\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_1196\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">19<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/academic.oup.com\/eurheartj\/article\/42\/5\/373\/5899003\">2020 Atrial fibrillation guidelines<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>SPARCtool<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1180\" data-linkid=\"1180\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_1180\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">28<\/span><button type=\"button\" style=\"\" id=\"link_dislike_1180\" data-linkid=\"1180\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_1180\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">14<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"http:\/\/www.sparctool.com\/\">Stroke Prevention in Atrial Fibrillation Risk Tool<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_2042\" data-linkid=\"2042\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_2042\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">33<\/span><button type=\"button\" style=\"\" id=\"link_dislike_2042\" data-linkid=\"2042\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_2042\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">12<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/guidance\/ng196\/chapter\/Recommendations\">2021 Atrial fibrillation guidelines<\/a><\/td><\/tr><\/table>","media":"<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/J33lfh6w3gI\" data-description=\"Understanding Atrial Fibrillation\" data-upvotes=\"0\" data-downvotes=\"1\" data-media=\"1688\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/J33lfh6w3gI\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/J33lfh6w3gI\" data-description=\"Understanding Atrial Fibrillation\" data-upvotes=\"0\" data-downvotes=\"1\" data-media=\"1688\">Understanding Atrial Fibrillation<\/a><\/td><\/tr><tr><td><span ><small>Zero To Finals - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_2865\" data-mediaid=\"2865\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_2865\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">0<\/span><button type=\"button\" style=\"\" id=\"media_dislike_2865\" data-mediaid=\"2865\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_2865\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">1<\/span><\/td><\/tr><\/table>","concepts_for_notes":{"1686":{"concept_text":"Anticoagulation should be considered for the following:\r\n   - Men: CHA2DS2-VASC >= 1\r\n   - Women CHA2DS2-VASC >= 2","concept_percentile":"69"},"3635":{"concept_text":"DOACs should be offered first-line for reducing stroke risk in AF","concept_percentile":"60"}},"category_name":"Cardiovascular","subcategory_name":"Cardiology","comment_count":18},"",[]]